While Janssen’s Tremfya and Sun Pharmaceutical’s Ilumya are Enjoying Continued Uptake, AbbVie’s Skyrizi (Risankizumab) is Shaping up to be a Major Disruptor to the US Psoriasis Market if Approved
Janssen’s ECLIPSE clinical trial data demonstrating sustained response of Tremfya in comparison to Novartis’ Cosentyx will have an impact on US dermatologists’ prescribing behavior, according to a recent study by Spherix Global Insights Download Report Overview EXTON, Pa., March 11, 2019 /PRNewswire/ —Spherix Global Insights’ 12th wave of RealTime Dynamix™: Psoriasis (US), which includes the feedback of 100 […]
Overall Use of Sanofi/Regeneron’s Dupixent for the Treatment of Atopic Dermatitis in the EU5 Lags that of the US, Though Side Effects and Short-Term Use in Both Markets May be Cause for Concern
Two reports recently published by Spherix Global Insights highlight key differences and similarities in the treatment of atopic dermatitis based on recent surveys of 364 US and EU5 dermatologists EXTON, Pa., February 27, 2019/PRNewswire/ — In the latest quarterly wave of RealTime Dynamix™: Atopic Dermatitis (US) published last week, US dermatologists (n=102) report continued uptake of […]
Spherix Global Insights’ Initial Report on the European Psoriasis Market Reveals Swift Uptake of Biosimilar Use at the Expense of AbbVie’s Humira
The recent launches of adalimumab biosimilars in the EU5 (France, Italy, Germany, Spain, and the UK) have resulted in a decrease in share for name brand Humira, while newly launched products such as Janssen’s Tremfya, UCB’s Cimzia, and Almirall’s Ilumetri are having a tougher time gaining traction. Download Report Overview EXTON, Pa., February 19, 2019 […]
Spherix Global Insights’ Annual Update of the Psoriasis Switching Market Reveals Significant Gains for Janssen’s Tremfya, Much to the Detriment of Sister-Brand Stelara
US dermatologists are keen on moving to a biologic with an alternative mechanism of action in the second- or later-line setting, with Tremfya claiming the title as biggest winner of the 2018 switching game Download Report Overview Exton, PA., November 20, 2018 / PRNewswire / — Biologic agents with alternate mechanisms of action (MOA) for […]
Sanofi/Regeneron’s Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment
With Dupixent only capturing a piece of the potential candidate pie, there remains ample runway for new agents in development to enter this highly dynamic market. Download Report Overview EXTON, Pa., Nov. 7, 2018 /PRNewswire/ – After over a year and a half on the market, U.S. dermatologists (n=102) remain extremely pleased with Sanofi/Regeneron’s Dupixent. In Spherix’s fourth quarter […]
Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron’s Dupixent
Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer’s PF-0496582, AbbVie’s upadacitinib and Incyte’s topical ruxolitinib have the most potential upside if approved Download Report Overview EXTON, Pa., September 27, 2018 (Newswire.com) – To better understand what real-world moderate and severe atopic dermatitis patients look like in terms of disease burden, physician […]
Latest Biologic Launch in Psoriasis, UCB’s Cimzia, Having a Tough Time Getting Traction, But Developing a Presence in Dermatology May Lay Foundation for Bimekizumab in the Future
Janssen’s Tremfya continues to post gains, but may soon face competition as Sun Dermatology readies for the launch of Ilumya (tildrakizumab), the second IL-23 inhibitor to be introduced in the U.S. market, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., September 14, 2018 (Newswire.com) – In the latest quarterly […]
Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron’s Dupixent, but Insurance Coverage and Out-of-Pocket Costs Continue to be Key Barriers for the Only Approved Atopic Dermatitis Biologic
According to the latest update from Spherix Global Insights, while dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis. Download Report Overview EXTON, Pa., August 15, 2018 /PRNewswire/ — Sanofi/Regeneron’s Dupixent continues to exceed expectations and current users […]
Bolstered Skin Clearance Allows for Ample First-Line Use of Biologics with Alternate Mechanisms of Action for the Treatment of Psoriasis
Data from over 1,000 psoriasis patients initiated on biologic or small molecule therapy for the first time reveals agents with alternate mechanisms of action–Janssen’s Stelara and Tremfya, Novartis’ Cosentyx, Eli Lilly’s Taltz, and Celgene’s Otezla, account for more than two-thirds of all recent first-line psoriasis initiations. Download Report Overview EXTON, Pa., June 28, 2018 /PRNewswire/ […]
US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics—Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya
Growth of the IL-17 inhibitors and Tremfya has been at the expense of the established TNF inhibitors and Janssen’s own Stelara. Download Report Overview EXTON, Pa., June 12, 2018 /PRNewswire/ — Spherix Global Insights’ second quarter update of RealTime Dynamix™: Psoriasis (US) reveals significant changes afoot in the current psoriasis biologic landscape. Year-over-year analysis indicates […]
